Antisense inhibitors, ribozymes, and siRNAs.
The current standard of care for the treatment of hepatitis C virus infection, pegylated interferon-alpha and ribavirin, is costly, associated with significant side effects, and effective in only 50% of patients. There is therefore a need for the development of novel antiviral therapies. One such approach involves the application of gene silencing technologies, including antisense oligonucleotides, ribozymes, RNA interference, and aptamers. However, despite great scientific advances over the past decade, and promising in vitro data, several significant challenges continue to limit the translation of this technology to the clinical setting. This review provides a concise update of the current literature.
Thompson
Alexander J V
AJ
Division of Gastroenterology/Hepatology, Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA.
Patel
Keyur
K
D015967:Gene Expression Regulation, Viral; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D035683:MicroRNAs / Q000737:chemistry; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000737:chemistry*; D034622:RNA Interference; D016337:RNA, Catalytic / Q000737:chemistry*; D034741:RNA, Small Interfering / Q000737:chemistry
D035683:MicroRNAs; D016376:Oligonucleotides, Antisense; D016337:RNA, Catalytic; D034741:RNA, Small Interfering